Stryker Co. (NYSE:SYK) VP M Kathryn Fink Sells 2,121 Shares

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,715,540. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

M Kathryn Fink also recently made the following trade(s):

• On Tuesday, September 17th, M Kathryn Fink sold 7,347 shares of Stryker stock. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06.

Stryker Price Performance

Shares of NYSE SYK traded down $8.01 during mid-day trading on Tuesday, reaching $363.95. The company’s stock had a trading volume of 1,399,099 shares, compared to its average volume of 1,291,955. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The stock has a 50-day moving average of $343.03 and a two-hundred day moving average of $342.53. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $374.63. The stock has a market capitalization of $138.65 billion, a P/E ratio of 42.46, a P/E/G ratio of 2.84 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. The firm had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 EPS. On average, equities research analysts anticipate that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s payout ratio is 36.53%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SYK shares. Evercore ISI dropped their price target on Stryker from $370.00 to $365.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Truist Financial reduced their price target on shares of Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a research report on Thursday, August 1st. Wolfe Research began coverage on shares of Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price objective on the stock. Needham & Company LLC boosted their target price on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Monday. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $378.58.

Institutional Trading of Stryker

Several institutional investors and hedge funds have recently bought and sold shares of SYK. Heritage Wealth Management Inc. purchased a new position in shares of Stryker during the 2nd quarter worth approximately $1,206,000. Sanctuary Advisors LLC acquired a new stake in shares of Stryker in the second quarter valued at $19,301,000. Clear Rock Advisors LLC raised its holdings in shares of Stryker by 1.4% in the 2nd quarter. Clear Rock Advisors LLC now owns 10,426 shares of the medical technology company’s stock valued at $3,547,000 after buying an additional 140 shares during the period. Centennial Bank AR increased its stake in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares during the period. Finally, Sycomore Asset Management grew its holdings in shares of Stryker by 149.9% in the second quarter. Sycomore Asset Management now owns 42,659 shares of the medical technology company’s stock valued at $14,526,000 after purchasing an additional 25,589 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.